BioCentury | Feb 4, 2020

Co-founded by UPenn’s Wilson, Passage Bio outlines clinical goals in new IPO filing

Less than a year after emerging from stealth mode, gene therapy company Passage Bio revealed new details about its pipeline and clinical timelines through the filing of a prospectus for its planned IPO. Founded in...
BC Innovations | Oct 10, 2017
Distillery Techniques


TECHNOLOGY: Gene profiling A panel of 17 genomic loci could help predict the risk of PD. Genome-wide association studies in a total of 20,084 PD patients and 397,324 healthy volunteers identified associations between the disease...
BC Extra | Sep 12, 2017
Preclinical News

Researchers identify 17 new PD risk loci

In a paper published in Nature Genetics , researchers from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY), 23andMe Inc. (Mountain View, Calif.) and colleagues conducted a meta-analysis of genome-wide association studies (GWAS) and identified 17...
BC Innovations | Apr 30, 2015
Distillery Therapeutics

Therapeutics: Galactosylceramidase (GALC)

Neurology INDICATION: Leukodystrophy Mouse studies suggest combining GALC gene therapy, the sphingolipid synthesis inhibitor L-cycloserine and bone marrow transplantation could help treat globoid cell leukodystrophy (Krabbe disease). Krabbe disease is caused by mutations in GALC...
Items per page:
1 - 4 of 4